Vascular Dementia Pipeline Insight
DelveInsight’s, “Vascular Dementia – Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Vascular Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Vascular Dementia Understanding
Vascular Dementia: Overview
Vascular dementia (VaD) is one of the most common causes of dementia after Alzheimer’s disease, causing around 15% of cases. Vascular dementia may result not only from large-vessel strokes (multi-infarct dementia) but also from ischemic lesions caused by small-vessel pathology, including lacunar strokes and incomplete white matter ischemia (subcortical ischemic vascular dementia), as well as from hypoperfusion caused by heart disease or circulatory disturbances. Cognitive changes in vascular dementia are much more variable than in other disorders such as Alzheimer’s disease, and are highly dependent on the particular neural substrates affected by the vascular pathology. Some symptoms may be similar to those of other types of dementia. Memory loss is common in the early stages of Alzheimer's, but is not usually the main early symptom of vascular dementia. Vascular dementia is caused by reduced blood supply to the brain due to diseased blood vessels. To be healthy and function properly, brain cells need a constant supply of blood to bring oxygen and nutrients. Blood is delivered to the brain through a network of vessels called the vascular system. If the vascular system within the brain becomes damaged - so that the blood vessels leak or become blocked - then blood cannot reach the brain cells and they will eventually die. There is currently no cure for vascular dementia: the brain damage that causes it cannot be reversed. However, there is a lot that can be done to enable someone to live well with the condition. This will involve drug and non-drug treatment, support and activities.
"Vascular Dementia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vascular Dementia pipeline landscape is provided which includes the disease overview and Vascular Dementia treatment guidelines. The assessment part of the report embraces, in depth Vascular Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Vascular Dementia.
Vascular Dementia Emerging Drugs Chapters
This segment of the Vascular Dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular Dementia Emerging Drugs
Akatinol Memantine: Merz Pharma
Akatinol Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine is marketed for the treatment of moderate to severe Alzheimer's disease. Memantine works by blocking NMDA receptors, to which the neurotransmitter glutamate normally attaches. Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another and overstimulation of the NMDA receptors can result in cell damage or death. The drug is in Phase III clinical development for the treatment of Vascular Dementia.
Butylphthalide soft capsules: CSPC Ouyi Pharmaceutical
Butylphthalide (NBP) is a compound found in Chinese celery seed extracts that can improve cognitive functions and may decrease Amyloid-beta levels in Alzheimer′s disease. NBP has antioxidant activities and may protect against oxidative/nitrosative stress, mitochondrial impairment and apoptosis. The drug is currently in Phase III stage of development for the treatment of patients with Vascular Dementia.
SaiLuoTong: Shineway Pharmaceutical
Sailuotong (SLT) capsule is a standardized three-herb preparation composed of ginseng, ginkgo, and saffron being evaluated for the treatment of vascular dementia in Phase III stage of development.
Further product details are provided in the report……..
Vascular Dementia: Therapeutic Assessment
This segment of the report provides insights about the different Vascular Dementia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Vascular Dementia
There are approx. 12+ key companies which are developing the therapies for Vascular Dementia. The companies which have their Vascular Dementia drug candidates in the most advanced stage, i.e. phase III include, Merz Pharma.
DelveInsight’s report covers around 12+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Vascular Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Vascular Dementia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vascular Dementia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular Dementia drugs.
Vascular Dementia Report Insights
- Vascular Dementia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Vascular Dementia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vascular Dementia drugs?
- How many Vascular Dementia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular Dementia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vascular Dementia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vascular Dementia and their status?
- What are the key designations that have been granted to the emerging drugs?